-
公开(公告)号：US20130171185A1
公开(公告)日：2013-07-04
申请号：US13808157
申请日：2011-07-05
IPC分类号： C07K14/08 , A61K39/295
CPC分类号： C07K14/005 , A61K39/12 , A61K39/295 , C07K14/08 , C07K2319/00 , C12N7/00 , C12N2770/16022 , C12N2770/16023
摘要： The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions.
摘要翻译： 本发明涉及含有第一诺如病毒株的VP1的S-结构域和含有第二诺如病毒株的VP1的至少一部分的P结构域的嵌合诺如病毒VP1蛋白质。 本发明还涉及编码嵌合VP1蛋白的核酸，含有嵌合诺如病毒VP1蛋白的病毒样颗粒和免疫原性组合物。
-
公开(公告)号：US07491808B2
公开(公告)日：2009-02-17
申请号：US11213326
申请日：2005-08-26
申请人： David Chien , Doris Coit , Celine Hu , Sansan Lin , Angelica Medina-Selby
发明人： David Chien , Doris Coit , Celine Hu , Sansan Lin , Angelica Medina-Selby
IPC分类号： C07H21/04
CPC分类号： G01N33/5767 , C07K14/005 , C12N2770/24222
摘要： Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.
摘要翻译： 描述了修饰的HCV非结构蛋白。 蛋白质包括修饰的NS3结构域，使得NS3分子的蛋白水解活性被抑制。 修饰的蛋白质保留构象表位。 还描述了包括经修饰的NS3分子的HCV免疫测定。
-
公开(公告)号：US07241879B2
公开(公告)日：2007-07-10
申请号：US10899715
申请日：2004-07-26
申请人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
发明人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
IPC分类号： C07H21/04
CPC分类号： C07K14/005 , C07K2319/00 , C12N2770/24222 , G01N33/5767 , G01N2333/18 , G01N2469/10 , G01N2469/20
摘要： HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.
摘要翻译： 提供包含NS3 / 4a构象表位和多表位融合抗原的HCV免疫测定，以及用于免疫测定的免疫测定固体支持物。
-
24.发明授权HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof 有权具有修饰的蛋白水解切割位点的HCV多表位融合抗原及其用途公开(公告)号：US07871625B2
公开(公告)日：2011-01-18
申请号：US11661577
申请日：2005-08-26
申请人： David Chien , Doris Coit , Carlos George-Nascimento , Sansan Lin , Angelica Medina-Selby , Laura Tandeske
发明人： David Chien , Doris Coit , Carlos George-Nascimento , Sansan Lin , Angelica Medina-Selby , Laura Tandeske
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222 , G01N33/5767 , G01N2469/20
摘要： Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.
摘要翻译： 描述了修饰的HCV多表位融合抗原（MEFA）。 蛋白质包括修饰的序列，使得HCV NS3蛋白酶对MEFAs的蛋白水解切割被抑制。 还描述了包括修饰的MEFAs的HCV免疫测定。
-
公开(公告)号：US06630298B2
公开(公告)日：2003-10-07
申请号：US09881239
申请日：2001-06-14
申请人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
发明人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
IPC分类号： C12Q170
CPC分类号： C07K14/005 , C07K2319/00 , C12N2770/24222 , G01N33/5767 , G01N2333/18 , G01N2469/10 , G01N2469/20
摘要： An HCV core antigen and NS3/4a antibody combination assay that can detect both HCV antigens and antibodies present in a sample using a single solid matrix, is provided, as well as immunoassay solid supports for use in the assay.
-
26.发明申请Hcv Multiple Epitope Fusion Antigens With Modified Proteolytic Cleavage Sites And Uses Thereof 有权Hcv多重表位融合抗原与修饰的蛋白水解切割位点及其用途公开(公告)号：US20080299544A1
公开(公告)日：2008-12-04
申请号：US11661577
申请日：2005-08-26
申请人： David Y Chien , Doris Coit , Carlos George-Nascimento , Sansan Lin , Angelica Medina-Selby , Laura Tandeske
发明人： David Y Chien , Doris Coit , Carlos George-Nascimento , Sansan Lin , Angelica Medina-Selby , Laura Tandeske
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222 , G01N33/5767 , G01N2469/20
摘要： Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.
摘要翻译： 描述了修饰的HCV多表位融合抗原（MEFA）。 蛋白质包括修饰的序列，使得HCV NS3蛋白酶对MEFAs的蛋白水解切割被抑制。 还描述了包括修饰的MEFAs的HCV免疫测定。
-
公开(公告)号：US20060088932A1
公开(公告)日：2006-04-27
申请号：US10733816
申请日：2003-12-10
申请人： Stephen Harrison , John Hall , Maria Calderon-Cacia , Ziyang Zhong , Eric Fang , Doris Coit , Steve Nguyen , Angelica Medina-Selby
发明人： Stephen Harrison , John Hall , Maria Calderon-Cacia , Ziyang Zhong , Eric Fang , Doris Coit , Steve Nguyen , Angelica Medina-Selby
CPC分类号： C12N9/1205 , C12Q1/485 , C12Y207/01037 , G01N2500/00
摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
-
公开(公告)号：US20130273109A1
公开(公告)日：2013-10-17
申请号：US13639820
申请日：2011-04-07
IPC分类号： A61K39/23
CPC分类号： A61K39/23 , A61K2039/5258 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N2750/14222 , C12N2750/14223 , C12N2750/14243 , C12N2830/20 , C12N2830/34 , Y02A50/412
摘要： The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.
摘要翻译： 本发明提供了产生细小病毒VP1 / VP2病毒样颗粒（VLP）的方法。 本发明还提供了用于纯化包含VLP的细小病毒VLP和免疫原性组合物的方法。 本发明还包括编码细小病毒VP1和VP2的重组核酸分子以及含有重组核酸的宿主细胞。
-
29.发明授权Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay 有权编码用于HCV抗原/抗体组合测定中的多表位融合抗原的多核苷酸公开(公告)号：US07319144B2
公开(公告)日：2008-01-15
申请号：US10643853
申请日：2003-08-19
申请人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
发明人： David Y. Chien , Phillip Arcangel , Laura Tandeske , Carlos George-Nascimento , Doris Coit , Angelica Medina-Selby
IPC分类号： C07H21/00 , C12N15/00 , C12N15/09 , C12N15/33 , C12N15/51 , C12P21/00 , A61K39/00 , A61K39/29
CPC分类号： C07K14/005 , C07K2319/00 , C12N2770/24222 , G01N33/5767 , G01N2333/18 , G01N2469/10 , G01N2469/20
摘要： The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4a epitope, and an HCV multiple epitope fusion antigen, that can detect both HCV antigens and antibodies present in a sample. The invention also includes polynucleotides encoding multiple epitope fusion antigens for use in the assay, recombinant vectors and host cells comprising such polynucleotides, and methods of producing the multiple epitope fusion antigens.
摘要翻译： 本发明涉及检测生物样品中HCV感染的方法，所述方法包括提供包含HCV抗核心抗体，包含HCV NS3 / 4a表位的抗原和HCV多表位融合抗原的免疫测定固体支持物， 其可以检测样品中存在的HCV抗原和抗体。 本发明还包括编码用于测定的多种表位融合抗原的多核苷酸，包含此类多核苷酸的重组载体和宿主细胞，以及产生多表位融合抗原的方法。
-
公开(公告)号：US20070249004A1
公开(公告)日：2007-10-25
申请号：US11704724
申请日：2007-02-08
申请人： Stephen Harrison , John Hall , Maria Calderon-Cacia , Ziyang Zhong , Eric Fang , Doris Coit , Steve Nguyen , Angelica Medina-Selby
发明人： Stephen Harrison , John Hall , Maria Calderon-Cacia , Ziyang Zhong , Eric Fang , Doris Coit , Steve Nguyen , Angelica Medina-Selby
IPC分类号： G01N33/53
CPC分类号： C12N9/1205 , C12Q1/485 , C12Y207/01037 , G01N2500/00
摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
摘要翻译： 本发明提供能够结晶的截短的GSK3多肽，包括GSK3α和GSK3β多肽，以及使用这些多肽来鉴定和优化GSK3抑制剂。 还提供了具有与野生型GSK3不同的至少一个取代的氨基酸的GSK3多肽，其中取代的氨基酸不能被磷酸化。 本发明用于提供鉴定和优化用于治疗由GSK3活性介导的疾病（包括阿尔茨海默病，2型糖尿病和炎症）的化合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
35 条记录 (耗时 0.03 秒)
